Allogene’s Cema-Cel Goes Express As Company Shifts To First-Line LBCL

Autoimmune CAR-T Could Sidestep Lymphodepletion

 
• By Alaric DeArment
  
Generate a summary of this article
Listen to this article
Beta

The allogeneic CAR-T developer announced a significant shift in its business strategy to develop its lead candidate in first-line consolidation of LBCL as the third-line disease setting becomes saturated.

Allogene announced a pivot to frontline consolidation of LBCL for its lead CAR-T candidate • Source: Shutterstock

Allogene Therapeutics Inc.’s decision to ditch the program for its lead CD19-directed allogeneic CAR-T cell therapy candidate, cemacabtagene ansegedleucel (cema-cel), in third-line large B-cell lymphoma (LBCL) and instead move it into the frontline consolidation setting opens up a much less saturated market opportunity, but some analysts have also pointed out that it could take a long time to bear fruit.

The centerpiece of the new strategy, announced on 4 January, is the planned pivotal Phase II ALPHA3 trial, testing cema-cel...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Strategy

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.